---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-002326"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:58:50.496682+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmuCell reports preliminary Q4 2024 sales of $7.8M, up 52% YoY; full year $26.5M

## Summary
- Q4 2024 product sales $7.8M vs $5.1M in Q4 2023 (+52%); FY2024 sales $26.5M vs $17.5M (+52%).
- Annualized Q4 production output ~103% of estimated $30M/year capacity; backlog fell to $4.4M from $9.4M.
- Contract manufacturer submitted response to FDA inspection observations; company filed Non-Administrative NADA for Re-Tain® in January.
- Conference call to discuss full unaudited results on February 26, 2025 at 9:00 AM ET.

## SEC filing metadata
- accession: 0001213900-25-002326
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390025002326/0001213900-25-002326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390025002326/ea0227158-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-002326
- JSON: https://secwatch.observer/filing/0001213900-25-002326.json
- Plain text: https://secwatch.observer/filing/0001213900-25-002326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.